← Back to All US Stocks

BMGL Stock Analysis - Basel Medical Group Ltd AI Rating

BMGL Nasdaq Services-Offices & Clinics of Doctors of Medicine D8 CIK: 0002004489
Recently Updated • Analysis: Mar 21, 2026 • SEC Data: 2026-03-21
AI Rating
STRONG SELL
95% Confidence

📊 BMGL Key Takeaways

Revenue: N/A
Net Margin: N/A
Free Cash Flow: N/A
Current Ratio: N/A
Debt/Equity: N/A
EPS: $0.00
AI Rating: STRONG SELL with 95% confidence

Investment Thesis

Basel Medical Group Ltd lacks sufficient financial data for meaningful fundamental analysis, with virtually all key metrics unavailable. The company appears to have minimal or no operational activity based on the absence of revenue, profitability, and cash flow data. Without verifiable financial information, the company presents an unquantifiable investment risk.

BMGL Strengths

  • -No strengths identified

BMGL Risks

  • ! No revenue data available - suggests either non-operational status or complete lack of financial transparency
  • ! Zero financial metrics across all categories (profitability, liquidity, leverage, cash flow) indicate either shell company status or complete operational failure
  • ! No insider activity in 90 days combined with absence of financial data suggests abandoned or dormant company status
  • ! Only 1 metric available out of standard financial reporting suite indicates severe data quality and disclosure issues
  • ! Inability to assess any fundamental health metric creates unacceptable analytical uncertainty

Key Metrics to Watch

BMGL Financial Metrics

Revenue
N/A
Net Income
N/A
EPS (Diluted)
$0.00
Free Cash Flow
N/A
Total Assets
N/A
Cash Position
N/A

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

BMGL Profitability Ratios

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA N/A
FCF Margin N/A

BMGL vs Default Sector

How Basel Medical Group Ltd compares to Default sector averages

Net Margin
BMGL 0.0%
vs
Sector Avg 12.0%
BMGL Sector
ROE
BMGL 0.0%
vs
Sector Avg 15.0%
BMGL Sector
Current Ratio
BMGL 0.0x
vs
Sector Avg 1.8x
BMGL Sector
Debt/Equity
BMGL 0.0x
vs
Sector Avg 0.7x
BMGL Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

BMGL Balance Sheet & Liquidity

Current Ratio
N/A
Quick Ratio
N/A
Debt/Equity
N/A
Debt/Assets
0.0%
Interest Coverage
N/A
Long-term Debt
N/A

BMGL Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

BMGL SEC Filings

Access official SEC EDGAR filings for Basel Medical Group Ltd (CIK: 0002004489)

Frequently Asked Questions about BMGL

What is the AI rating for BMGL?

Basel Medical Group Ltd (BMGL) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.

What are BMGL's key strengths?

.

What are the risks of investing in BMGL?

No revenue data available - suggests either non-operational status or complete lack of financial transparency. Zero financial metrics across all categories (profitability, liquidity, leverage, cash flow) indicate either shell company status or complete operational failure.

What is BMGL's revenue and growth?

Basel Medical Group Ltd reported revenue of N/A.

Does BMGL pay dividends?

Basel Medical Group Ltd does not currently pay dividends.

Where can I find BMGL SEC filings?

Official SEC filings for Basel Medical Group Ltd (CIK: 0002004489) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is BMGL's EPS?

Basel Medical Group Ltd has a diluted EPS of $0.00.

How is the AI analysis conducted?

Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.

Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 21, 2026 | Data as of: 2026-03-21 | Powered by Claude AI